Topics

Synteract Bolsters Its Oncology, Neuro Degenerative and Rare Disease Centers of Development with Two New Executives

10:00 EDT 30 Apr 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Christopher Heckman to focus on Oncology Center of Development as Dr. Art Wamil joins as lead neurologist Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, con...

Other Sources for this Article

Beth Walsh
beth@clearpointagency.com
760-230-2424

NEXT ARTICLE

More From BioPortfolio on "Synteract Bolsters Its Oncology, Neuro Degenerative and Rare Disease Centers of Development with Two New Executives"

Quick Search

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Antiretroviral therapy
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...